To report SUSPECTED ADVERSE REACTIONS, contact argenx at 1-833-argx411 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch
Resource Library
To report SUSPECTED ADVERSE REACTIONS, contact argenx at 1-833-argx411 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch
To report SUSPECTED ADVERSE REACTIONS, contact argenx at 1-833-argx411 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch
Myasthenia Gravis
European Academy of Neurology (EAN)
June 28 - July 1, 2024
-
Helsinki, Finland
European Academy of Neurology (EAN)
June 28 - July 1, 2024
-
Helsinki, Finland
Poster
- Achievement of Minimal Symptom Expression in Participants Treated With Efgartigimod in ADAPT+ and ADAPT-SC+
- COVID-19 Vaccination Response in Participants Receiving Efgartigimod IV or Efgartigimod PH20 SC in ADAPT+ or ADAPT-SC+
- Efficacy and Safety of Efgartigimod IV and PH20 SC in gMG: Analysis of AChR-Ab− Participants in ADAPT+/ADAPT-SC+
- Efgartigimod Consistently Improved Health-Related Quality of Life in AChR-Ab+ Participants With gMG in IV and SC Trials
- Fixed Cycle and Every-Other-Week Dosing of Intravenous Efgartigimod for Generalised Myasthenia Gravis: Part A of ADAPT NXT
- Long-Term Safety and Efficacy of Subcutaneous Efgartigimod PH20: Interim Results of the ADAPT-SC+ Trial
- Real world reduction in oral corticosteroid utilization following efgartigimod initiation
- Safety Profile of Intravenous Efgartigimod From Clinical Trials in Immunoglobulin G–Mediated Autoimmune Diseases
- Steroid toxicity in adults with myasthenia gravis in the United States based on electronic health records
- Subcutaneous Efgartigimod PH20 Demonstrates Improvements in gMG Patients Regardless of Prior Administration Route
European Academy of Neurology (EAN)
June 28 - July 1, 2024
-
Helsinki, Finland
European Academy of Neurology (EAN)
June 28 - July 1, 2024
-
Helsinki, Finland
Japanese Society of Neurology (JSN)
May 28 - 31, 2024
-
Tokyo, Japan
Japanese Society of Neurology (JSN)
May 28 - 31, 2024
-
Tokyo, Japan
Canadian Neurological Sciences Federation (CNSF)
May 19 - 25, 2024
-
Toronto, ON, Canada
Canadian Neurological Sciences Federation (CNSF)
May 19 - 25, 2024
-
Toronto, ON, Canada
Canadian Neurological Sciences Federation (CNSF)
May 19 - 25, 2024
-
Toronto, ON, Canada
Canadian Neurological Sciences Federation (CNSF)
May 19 - 25, 2024
-
Toronto, ON, Canada
Poster
International Society for Pharmacoeconomics and Outcomes Research (ISPOR)
May 4 - 7, 2024
-
Atlanta, GA, USA
International Society for Pharmacoeconomics and Outcomes Research (ISPOR)
May 4 - 7, 2024
-
Atlanta, GA, USA
Poster
- Exploring the Impact of Non-steroidal Immunosuppressive Drugs and Steroids on the Development of Comorbidities in Patients with Myasthenia Gravis in the National Veterans Affairs Health
- Adaptation of the Glucocorticoid Toxicity Index-Metabolic Domains Instrument to Evaluate Glucocorticoid Toxicity in Adults with Myasthenia Gravis using Electronic Health Records in the United States
- Comorbidities in Myasthenia Gravis in the US National Veterans Affairs Health Network
- Impact of Glucocorticoid Use on Mortality in Adults with Chronic Diseases: A Systematic Literature Review
American Academy of Neurology (AAN)
April 12 - 17, 2024
-
Denver, CO
American Academy of Neurology (AAN)
April 12 - 17, 2024
-
Denver, CO
Poster
- Fixed Cycle and Every-Other-Week Dosing of Intravenous Efgartigimod for Generalized Myasthenia Gravis: Part A of ADAPT NXT
- Long-Term Safety, Tolerability, and Efficacy of Subcutaneous Efgartigimod PH20 in Participants With Generalized Myasthenia Gravis: Interim Results of the ADAPT-SC+ Study
- Analysis of Serious Infections and Malignancy Risk in Myasthenia Gravis: A US Claims Database Study
- Achievement of Minimal Symptom Expression and Effect on Disease-Specific Measures in Acetylcholine Receptor Antibody-Positive Participants With Generalized Myasthenia Gravis Treated With Efgartigimod in ADAPT/ADAPT+
- Cost-effectiveness analysis of efgartigimod versus chronic intravenous immunoglobulin (IVIg) for treatment of acetylcholine receptor antibody positive (AChR-Ab+) generalized myasthenia gravis (gMG) in Canada
- Overview of the Safety Profile of Efgartigimod Clinical Trials in Participants With Diverse IgG-Mediated Autoimmune Diseases
American Academy of Neurology (AAN)
April 12 - 17, 2024
-
Denver, CO
American Academy of Neurology (AAN)
April 12 - 17, 2024
-
Denver, CO
Oral Presentations
Global Conference on Myositis (GCOM)
March 12 - 15, 2024
-
Pittsburg, PA
Global Conference on Myositis (GCOM)
March 12 - 15, 2024
-
Pittsburg, PA
Muscular Dystrophy Association (MDA)
March 2 - 5, 2024
-
Orlando, FL
Muscular Dystrophy Association (MDA)
March 2 - 5, 2024
-
Orlando, FL
Muscular Dystrophy Association (MDA)
March 2 - 5, 2024
-
Orlando, FL
Muscular Dystrophy Association (MDA)
March 2 - 5, 2024
-
Orlando, FL
American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM)
October 31 - November 3, 2023
-
Phoenix, AZ
American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM)
October 31 - November 3, 2023
-
Phoenix, AZ
Posters
- LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF EFGARTIGIMOD IN PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS: CONCLUDING ANALYSES FROM THE ADAPT+ STUDY
- DOSE SELECTION AND CLINICAL DEVELOPMENT OF EFGARTIGIMOD PH20 SUBCUTANEOUS IN PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS
- LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF SUBCUTANEOUS EFGARTIGIMOD PH20 IN PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS: INTERIM RESULTS OF THE ADAPT-SC+ STUDY
- LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF SUBCUTANEOUS EFGARTIGIMOD PH20 IN PARTICIPANTS WITH GENERALIZED MYASTHENIA GRAVIS: INTERIM ANALYSIS OF ANTI-ACETYLCHOLINE RECEPTOR AUTOANTIBODY SERONEGATIVE PARTICIPANTS IN THE ADAPT-SC+ STUDY
- A CASE OF TREATMENT WITH EFGARTIGIMOD IN A PATIENT WITH GENERALIZED MYASTHENIA GRAVIS AND LRP4 ANTIBODIES
- TREATMENT-RELATED INEQUITIES IN PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS FACING SOCIAL DETERMINANTS OF HEALTH CHALLENGES: A SURVEY OF NEUROLOGISTS IN THE UNITED STATES
- DIAGNOSTIC INEQUITIES IN PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS FACING SOCIAL DETERMINANTS OF HEALTH CHALLENGES: A SURVEY OF NEUROLOGISTS IN THE UNITED STATES
- EFGARTIGIMOD IN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP): FINAL RESULTS FROM THE ADHERE TRIAL
- OVERVIEW OF THE SAFETY PROFILE FROM EFGARTIGIMOD CLINICAL TRIALS IN PARTICIPANTS WITH DIVERSE IGG-MEDIATED AUTOIMMUNE DISEASES
Myasthenia Gravis Foundation of America (MGFA)
October 31 - November 3, 2023
-
Phoenix, AZ
Myasthenia Gravis Foundation of America (MGFA)
October 31 - November 3, 2023
-
Phoenix, AZ
Posters
- HUMORAL IMMUNE RESPONSE TO POLYVALENT PNEUMOCOCCAL VACCINE IN HEALTHY PARTICIPANTS RECEIVING EFGARTIGIMOD
- SUBCUTANEOUS EFGARTIGIMOD PH20 TREATMENT IN PARTICIPANTS WITH GENERALIZED MYASTHENIA GRAVIS IN ADAPT-SC+: INTERIM ANALYSES ON QUALITY OF LIFE, EFFICACY, TOLERABILITY, AND LONG-TERM SAFETY
- REAL-WORLD OUTCOMES OF PATIENTS LIVING WITH GENERALIZED MYASTHENIA GRAVIS INITIATING EFGARTIGIMOD TREATMENT IN THE UNITED STATES
- RACIAL DISPARITIES IN ACUTE CARE UTILIZATION OUTCOMES AMONG THOSE WITH MYASTHENIA GRAVIS
- NETWORK META ANALYSIS OF TREATMENT OPTIONS IN GENERALIZED MYASTHENIA GRAVIS: IMPACT ON HEALTH-RELATED QUALITY OF LIFE
- ASSOCIATION BETWEEN PATIENT SUPPORT PROGRAM PARTICIPATION AND ACCESS TO EFGARTIGIMOD TREATMENT FOR GENERALIZED MYASTHENIA GRAVIS
- REAL-WORLD BURDEN ASSOCIATED WITH SOCIAL DETERMINANTS OF HEALTH CHALLENGES FOR INDIVIDUALS LIVING WITH GENERALIZED MYASTHENIA GRAVIS IN THE UNITED STATES
- ACHIEVEMENT OF MINIMAL SYMPTOM EXPRESSION IN ACETYLCHOLINE-RECEPTOR ANTIBODY-POSITIVE PARTICIPANTS WITH GENERALIZED MYASTHENIA GRAVIS AND EFFECT ON DISEASE-SPECIFIC MEASURES IN ADAPT/ADAPT+ STUDIES
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
European Academy of Neurology (EAN)
June 28 - July 1, 2024
-
Helsinki, Finland
European Academy of Neurology (EAN)
June 28 - July 1, 2024
-
Helsinki, Finland
Peripheral Nerve Society (PNS)
June 21 - 24, 2024
-
Montréal, Quebec, Canada
Peripheral Nerve Society (PNS)
June 21 - 24, 2024
-
Montréal, Quebec, Canada
Japanese Society of Neurology (JSN)
May 28 - 31, 2024
-
Tokyo, Japan
Japanese Society of Neurology (JSN)
May 28 - 31, 2024
-
Tokyo, Japan
Canadian Neurological Sciences Federation (CNSF)
May 19 - 25, 2024
-
Toronto, ON, Canada
Canadian Neurological Sciences Federation (CNSF)
May 19 - 25, 2024
-
Toronto, ON, Canada
International Society for Pharmacoeconomics and Outcomes Research (ISPOR)
May 4 - 7, 2024
-
Atlanta, GA, USA
International Society for Pharmacoeconomics and Outcomes Research (ISPOR)
May 4 - 7, 2024
-
Atlanta, GA, USA
Poster
- Comparison of patient identification methodologies in chronic inflammatory demyelinating polyneuropathy using United States administrative claims data
- Burden of illness for adults with chronic inflammatory demyelinating polyneuropathy in the United States
- Real-world treatment patterns in adults with chronic inflammatory demyelinating polyneuropathy in the United States
- Validation of treatment patterns in adults with chronic inflammatory demyelinating polyneuropathy in the United States using administrative claims datasets
Peripheral Nerve Society (PNS)
June 16 - 19, 2023
-
Copenhagen, Denmark
Peripheral Nerve Society (PNS)
June 16 - 19, 2023
-
Copenhagen, Denmark
Thyroid Eye Disease
International Society for Pharmacoeconomics and Outcomes Research (ISPOR)
May 4 - 7, 2024
-
Atlanta, GA, USA
International Society for Pharmacoeconomics and Outcomes Research (ISPOR)
May 4 - 7, 2024
-
Atlanta, GA, USA
Multifocal Motor Neuropathy (MMN)
European Academy of Neurology (EAN)
June 28 - July 1, 2024
-
Helsinki, Finland
European Academy of Neurology (EAN)
June 28 - July 1, 2024
-
Helsinki, Finland
European Academy of Neurology (EAN)
June 28 - July 1, 2024
-
Helsinki, Finland
European Academy of Neurology (EAN)
June 28 - July 1, 2024
-
Helsinki, Finland
Peripheral Nerve Society (PNS)
June 21 - 24, 2024
-
Montréal, Quebec, Canada
Peripheral Nerve Society (PNS)
June 21 - 24, 2024
-
Montréal, Quebec, Canada
To report SUSPECTED ADVERSE REACTIONS, contact argenx at 1-833-argx411 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch
VYVGART is a registered trademark of argenx. VYVGART Hytrulo is a trademark of argenx.
© 2024 argenx MED-US-NON-2400036 v0.8 7/2024. All Rights Reserved.